Recruiting
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
NCT05266846
- Conditions
- ALK Gene Mutation, Adenocarcinoma, Adenocarcinoma of Lung, +10 more
- Locations
-
- Hunan Cancer Hospital Changsha, Hunan, China